These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18839141)

  • 1. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.
    Finfer S; Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Gårdlund B; Marshall JC; Rhodes A
    Intensive Care Med; 2008 Nov; 34(11):1935-47. PubMed ID: 18839141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editors' comments on a new trial of activated protein C for persistent septic shock.
    Mancebo J; Antonelli M
    Intensive Care Med; 2008 Nov; 34(11):1948-9. PubMed ID: 18839138
    [No Abstract]   [Full Text] [Related]  

  • 3. Science, medicine and industry: are we getting out of the black hole in sepsis research?
    Suter PM; Takala J
    Intensive Care Med; 2008 Nov; 34(11):1950-4. PubMed ID: 18839139
    [No Abstract]   [Full Text] [Related]  

  • 4. Once is not enough: clinical trials in sepsis.
    Sweeney DA; Danner RL; Eichacker PQ; Natanson C
    Intensive Care Med; 2008 Nov; 34(11):1955-60. PubMed ID: 18839140
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial.
    Annane D; Timsit JF; Megarbane B; Martin C; Misset B; Mourvillier B; Siami S; Chagnon JL; Constantin JM; Petitpas F; Souweine B; Amathieu R; Forceville X; Charpentier C; Tesnière A; Chastre J; Bohe J; Colin G; Cariou A; Renault A; Brun-Buisson C; Bellissant E;
    Am J Respir Crit Care Med; 2013 May; 187(10):1091-7. PubMed ID: 23525934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated protein C and septic shock: a propensity-matched cohort study*.
    Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
    Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prowess-shock trial: a protocol overview and perspectives.
    Silva E; de Figueiredo LF; Colombari F
    Shock; 2010 Sep; 34 Suppl 1():48-53. PubMed ID: 20523271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.
    Lai PS; Matteau A; Iddriss A; Hawes JC; Ranieri V; Thompson BT
    Minerva Anestesiol; 2013 Jan; 79(1):33-43. PubMed ID: 23174922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endogenous anticoagulant therapy for sepsis. Success and failure].
    Wiedermann CJ
    Internist (Berl); 2007 May; 48(5):537-42, 544. PubMed ID: 17390117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stopping trials early for benefit--not so fast!
    Faust AC; Chung T; Feldman M
    Ann Pharmacother; 2012 Nov; 46(11):1564-7. PubMed ID: 23136354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroids and human recombinant activated protein C for septic shock.
    Colin G; Annane D
    Clin Chest Med; 2008 Dec; 29(4):705-12, x. PubMed ID: 18954704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drotrecogin alfa (activated) in adults with septic shock.
    Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
    N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [PROWESS--milestone in lowering sepsis mortality].
    Reinhart K
    Krankenpfl J; 2002; 40(10-12):315. PubMed ID: 12600016
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
    Dhainaut JF; Laterre PF; LaRosa SP; Levy H; Garber GE; Heiselman D; Kinasewitz GT; Light RB; Morris P; Schein R; Sollet JP; Bates BM; Utterback BG; Maki D
    Crit Care Med; 2003 Sep; 31(9):2291-301. PubMed ID: 14501959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drotrecogin alfa: new preparation. For some cases of severe sepsis?
    Prescrire Int; 2003 Apr; 12(64):55-7. PubMed ID: 12674116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "All in" for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.
    Barie PS
    Surg Infect (Larchmt); 2007 Oct; 8(5):491-4. PubMed ID: 17999581
    [No Abstract]   [Full Text] [Related]  

  • 17. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
    Crum NF; Groff HL; Parrish JS; Ring W
    Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) treatment in a neonate with sepsis and multi organ failure.
    Albuali WH; Singh RN; Fraser DD; Scott LA; Kornecki A
    Saudi Med J; 2005 Aug; 26(8):1289-92. PubMed ID: 16127532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recently published papers: Sepsis--guidelines, treatment and novel approaches.
    Kalsi N; Forni LG
    Crit Care; 2008; 12(2):120. PubMed ID: 18394177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.